Cardioprotezione ed invecchiamento

Similar documents
Ischemia and Reperfusion: Pharmacological treatment options

Reactive oxygen species: Importance for ischemia/reperfusion (injury)

CLINICAL APPLICATION OF ISCHEMIC PRECONDITIONING IN THE ELDERLY

Reperfusion Injury: How Can We Reduce It?

cardiac pre and post conditioning

Disclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin

Sean Davidson. The Hatter Cardiovascular Institute University College London, UK

Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy

Reperfusion Effects After Cardiac Ischemia

Journal of the American College of Cardiology Vol. 38, No. 4, by the American College of Cardiology ISSN /01/$20.

Loss of Preconditioning by Attenuated Activation of Myocardial ATP-Sensitive Potassium Channels in Elderly Patients Undergoing Coronary Angioplasty

Nuovi target e opportunità terapeutiche del danno da riperfusione nello STEMI

Journal of the American College of Cardiology Vol. 38, No. 5, by the American College of Cardiology ISSN /01/$20.

Coronary heart disease (CHD)

Ameliorating Reperfusion Injury During Resuscitation from Cardiac Arrest

Basic Mechanisms of Remote Ischemic Conditioning

Master Eudipharm 2012 Introductory Module, Principles of Discovery of Medicine and Development Planning. Nathan Mewton, MD, PhD. September 26 th 2012

Pathophysiology of ischemia-reperfusion injury (and how to protect against it )

CONSEQUENCES OF MYOCARDIAL ISCHEMIA

Ischemic heart disease

Myocardial ischaemia reperfusion injury: the challenge of translating ischaemic and anaesthetic protection from animal models to humans

Rational use of imaging for viability evaluation

Remote Ischemic Preconditioning: Current aspects of mechanisms. Hans Erik Bøtker, Aarhus University Hospital, Skejby, Denmark,

Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )

presenters 2010 Sameh Sabet Ain Shams University

Gated blood pool ventriculography: Is there still a role in myocardial viability?

Prevention of reperfusion injury in STEMI - Contra

12 Lead EKG Chapter 4 Worksheet

OBJECTIVES BACKGROUND METHODS

Coronary Revascularization for Severe LV Dysfunction Is s. Is the concept of viability testing still viable?

MR Assessment of Myocardial Viability

Typical chest pain with normal ECG

Basic and Clinical Aspects of Ischemic Preconditioning

ATEF ELBAHRY,FACA,FICA,MISCP,FVBWG.

ELECTROPHYSIOLOGICAL CHANGES DURING MYOCARDIAL ISCHAEMIA

Old and new insights into viability:perfusion and Perfusion Reserve

Heart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United

Rationale for Prophylactic Support During Percutaneous Coronary Intervention

There are numerous reviews on the signal transduction of

EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: , 2014

Revascularization In HFrEF: Are We Close To The Truth. Ali Almasood

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

Assessment of Ischemia and Viability

Ischemia-reperfusion injury (IRI) complicates myocardial

What about aborted infarction?

The role of cardiac mitochondria in myocardial ischemia/reperfusion injury. Chad R. Frasier. April, 2012

Modificazioni età-correlate del signaling β-adrenergico e basi molecolari dell'utilizzo dei β-bloccanti

Coronary interventions

c Ischemia (30 min) Reperfusion (8 w) Supplementary Figure bp 300 bp Ischemia (30 min) Reperfusion (4 h) Dox 20 mg/kg i.p.

Myocardial ischemic preconditioning (IP) has been extensively

Adjunctive Therapy to Reduce Infarct Size: Current and Future Challenges

Cardiogenic Shock. Dr. JPS Henriques. Academic Medical Center University of Amsterdam The Netherlands

Management of Cardiogenic shock. Prof. Christian JM Vrints

Joost Seeger. A thesis submitted in partial fulfilment of the requirements of Liverpool John Moores University for the degree of Doctor of Philosophy.

Ischemic Heart Failure

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

In the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension

Myocardial Infarction

Value of cardiac rehabilitation Prof. Dr. L Vanhees

Insights into Viability- Function and Contractile Reserve

Reperfusion Injury, Cardioprotection, and 2 Decades of Failed Studies

Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning

BEER AND THE HEART: INSIGHTS ON THE EFFECTS ON ALCOHOLIC AND NON-ALCOHOLIC BEER

Cardiogenic Shock. Carlos Cafri,, MD

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Cardiac Viability Testing A Clinical Perspective Annual Cardiac Imaging Symposium. Lisa M Mielniczuk MD FRCPC University of Ottawa Heart Institute

Ventricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center

Value of Assessment of Viable and Ischemic Myocardium and Techniques Such as MRI, Radionuclide Imaging

DECLARATION OF CONFLICT OF INTEREST

Χ.Τρίκκα Καρδιολογική Κλινική Νοζοκομείο Ερρίκος Νησνάν

Ischemic Heart Failure

Drug Treatment of Ischemic Heart Disease

SHOCKWAVE THERAPY FOR REFRACTORY ANGINA PECTORIS

Supplementary Figure 1. Confocal immunofluorescence showing mitochondrial translocation of Drp1. Cardiomyocytes treated with H 2 O 2 were prestained

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology

Borja Ibanez, MD PhD FESC. - Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC). - Fundación Jiménez Díaz Hospital.

Revascularization of ischemic LV dysfunction: past, present and future

Integrative cardiovascular physiology: a primer to hypothesis driven research

University of Milan spin-off founded in 2004 and now fully owned by Genextra S.p.A.

Coronary Revascularization in Patients witj Severe LV Dysfunction.: Is the concept of viability still viable?

Screening for Asymptomatic Coronary Artery Disease: When, How, and Why?

CORONARY ARTERY DISEASES

The life after myocardial infarction: a long quiet river?

Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies

Mechanisms and role of contrast echocardiography

OUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand

Management of the coronary patient in Roberto Ferrari

Angiotensin-converting enzyme inhibitors potentiate subthreshold preconditioning through NO and mitok ATP. channel

Improving STEMI outcomes in Denmark. Michael Rahbek Schmidt, MD, PhD. Aarhus University Hospital Skejby Denmark

Management of stable CAD FFR guided therapy: the new gold standard

Recovering Hearts. Saving Lives.

CPR flow to prime the ischemic heart during cardiac arrest?

6. Lochner, A., Tromp, E., Mouton, R. Signal transduction in myocardial ischaemia and reperfusion. Mol Cell Biochem., 160/161: , 1996.

Forum Minireview. Tetsuji Miura 1, *, Masahiro Nishihara 1, and Takayuki Miki 1

1) Severe, crushing substernal chest pain 2) radiate to the neck, jaw, epigastrium, or left arm. 3- rapid and weak pulse 4- nausea (posterior MI).

Fetal gene upregulation by 1-wk TAC is significantly increased in mice lacking RGS2.

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Novel Strategies in Cardioprotection against Ischemia/Reperfusion Injury

Transcription:

55 Congresso SIGG Invecchiamento e longevità: più geni o più ambiente? Firenze, 30/11/2010-04/12/2010 Palazzo dei Congressi SESSIONE DI BIOGERONTOLOGIA Cardioprotezione ed invecchiamento P. Abete, MD, PhD Dipartimento di Medicina Clinica, Scienze Cardiovascolari ed Immunologiche, Cattedra di Geriatria, Università di Napoli Federico II

Cardioprotection and aging Cardioprotection: definition Myocardial stunning, hibernation, and ischemic preconditioning Cardioprotection and aging: why? Age-related reduction of cardioprotection Restoration of age-related reduction of cardioprotection Future directions

Cardioprotection and aging Cardioprotection: definition Myocardial stunning, hibernation, and ischemic preconditioning Cardioprotection and aging: why? Age-related reduction of cardioprotection Restoration of age-related reduction of cardioprotection Future directions

Cardioprotection: definition Myocardial ischemia is the result of an imbalance between myocardial oxygen supply and demand and it was thought to result in irreversible myocyte damage. anti-ischemic It is now demonstrated that in cardiac tissue, submitted to the vaccination!! stress of oxygen and substrate deprivation, endogenous mechanisms of cell survival may be activated. These molecular mechanisms result in physiological conditions of adaptation to ischemia defining the concept of endogenous cardioprotection. Boengler K et al. Cardiovasc Res 2009

Cardioprotection and aging Cardioprotection: definition Myocardial stunning, hibernation, and ischemic preconditioning Cardioprotection and aging: why? Age-related reduction of cardioprotection Restoration of age-related reduction of cardioprotection Future directions

MYOCARDIAL HIBERNATION Rahimtoola SH Circulation 1985 MYOCARDIAL STUNNING Heyndrickx GR et al. J Clin Invest 1975 ISCHEMIC PRECONDITIONING Murry CE et al. Circulation 1986

Myocardial stunning Prolonged and fully reversible dysfunction of the ischemic heart which persists after reperfusion despite the normalization of blood flow. Stunning can occur in a number of conditioning following: exercise in the presence of a flow limiting stenosis myocardial infarction where the subendocardium is infarcted and the subepicardium may be stunned for a prolonged period of time; ischemic bout that is induced by angioplasty; ect. Depre C & Vatner SF, Heart Fail Rev 2007

Myocardial stunning stunning FLOW-FUNCTION MISMATCH Reperfusion CS=Coronary Stenosis CS 100% Depre C & Vatner SF, Heart Fail Rev 2007

Myocardial hibernation Myocardial hibernation represents a condition of chronic ventricular dysfunction in patients with coronary artery disease, which is progressively reversible after revascularization. Myocardial hibernation represent a condition in which: a concomitant reduction in coronary blood flow is present; myocardial necrosis is not present; consequently, myocardial metabolism and function are both reduced. Depre C & Vatner SF, Heart Fail Rev 2007

Myocardial hibernation hibernation SMART HEART HYPOTHESIS Flow reduction to 20% Depre C & Vatner SF, Heart Fail Rev 2007

Ischemic preconditioning Ischemic preconditioning represents a protection against irreversible damage conferred by brief and repetitive episodes of occlusion/reperfusion preceding a longer episode of potentially lethal Ischemia. The phenomenon is independent of increased collateral blood flow. Ischemic preconditioning occurs in the following conditions: Preinfarction angina Warm-up phenomenon Walk through angina Coronary angioplasty Murry CE et al., Circulation 1986

Ischemic preconditioning Infarct size (%) Murry CE et al., Circulation 1986

Linking stunning, hibernation, and ischemic preconditioning There is some evidence that myocardial viability cannot be maintained during sustained moderate ischemia for more than a few hours but that chronic hibernation results from repetitive bouts of ischemia-reperfusion; Accordingly, repetitive episodes of ischemic dysfunction followed by stunning create a sustained depression of contractile function; In this context, ischemic preconditioning seems to play a key role in the cardioprotection.

Metabolic adaptation during a sequence of no-flow and low-flow ischemia Preconditioning triggers for hibernation? low-flow 2.2 ml/min 10 min. 0 - flow, Ischemic preconditioning! low-flow 2.2 ml/min Ferrari R et al., Circulation 1996

SURVIVAL HYPOTHESIS CORONARY STENOSIS Decreased blood flow at rest Decreased metabolism Decreased fuction HIBERNATION Mantained blood flow at rest Repetitive ischemia and reperfusion Chronic STUNNING Chronically depressed Contractile function activation of PRECONDITIONING Depre C & Vatner SF, Heart Fail Rev 2007

Cardioprotection and aging Cardioprotection: definition Myocardial stunning, hibernation, and ischemic preconditioning Cardioprotection and aging: why? Age-related reduction of cardioprotection Restoration of age-related reduction of cardioprotection Future directions

Number of patients in the USA with a heart attack according to age and sex Health Statistics, National Heart, Lung, and Blood Institute, Circulation 2007

Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis Odds Ratio (OR) 20 15 10 61-65 10.1 5.3 (1.5-18.2) 5 76-80OR 18.9 % 20 66-70 12.214.7 (3.5-42.3) 8.5 (2.4-29.1) 0 Age CK >6 x normal 30 40 50 60 70 80 90 Age (years) Age % Mortality OR (95%CI) 80 <40 1.9 1 Mortality 41-45 OR 2.2 (95%CI) 3.7 (0.9-14.7) 60 46-50 3.1 2.0 (0.5-7.7) 51-55 3.5 % 3.1 (0.8-10.9) > 6 leads 40 (%) 0 51-55 3.5 3.1 (0.8-10.9) 56-60 5.8 3.9 (1.1-13.6) 71-75 18.9 10.1 (2.9-34.8) 76-80 18.9 12.2 (3.5-42.3) >80 31.9 18.8 (5.3-66.8) Maggioni AP et al., N Engl J Med 1993

Factors leading to shorter survival after acute myocardial infarction in patients aged 65 to 75 years compared with younger patients Mortality (%) 60 50 40 30 20 65-75 years Not adjusted p < 0.001 Mortality (%) 60 50 40 30 20 Adjusted for COMORBIDITY p < 0.02 65-75 years 10 0 < 64 years 0 12 24 36 48 10 0 < 64 years 0 12 24 36 48 Months Months Tofler GH et al, Am J Cardiol 1988

Cardioprotection and aging Cardioprotection: definition Myocardial stunning, hibernation, and ischemic preconditioning Cardioprotection and aging: why? Age-related reduction of cardioprotection Restoration of age-related reduction of cardioprotection Future directions

MYOCARDIAL STUNNING is more evident in senescent than in adult heart Stunning *p<0.01 vs senescent Abete P et al., Exp Gerontol 1999

MYOCARDIAL HIBERNATION reduces contractile function more in senescent than in adult heart 100 Hibernation Developed pressure (% of baseline) 80 60 40 20 * * * * 0 66 59 51 44 37 37 37 37 Coronary perfusion pressure, mmhg Abete P et al., Exp Gerontol 1999

PRECONDITIONING does not prevent postischemic dysfunction in aging heart Ischemic preconditioning B Ischemia Reperfusion B IP Ischemia Reperfusion 100 80 100 80 * * * Adult DP (%) 60 40 Adult Senescent DP (%) 60 40 Senescent 20 20 0-10 0 10 20 30 40 50 60 70 80 90 Time (min) 0-10 0 10 20 30 40 50 60 70 80 90 Time (min) P<0.001 vs senescent P. Abete et al., JACC 1996

Effect of one 5-min preconditioning cycle (1PC) and three 5-min preconditioning cycles (3PC) on infarct size in young-adult, middle-aged, and aged rat hearts Schulman D et al., J Am Physiol 2001

Angina-induced protection against myocardial infarction in adult and elderly patients: a loss of preconditioning mechanism in the aging heart? 16 14 p < 0.01 p = 0.27 (NS) Angina No Angina 12 Mortality (%) 10 8 6 4 2 0 Adults Elderly P. Abete et al., JACC 1997

5-years survival curves in adult and elderly patients with and without preinfarction angina 100 Adults 100 Elderly 80 80 Survival (%) 60 40 20 p=0.007 Preinfarction angina (+) Preinfarction angina (-) Survival (%) 60 40 20 p=0.47 (NS) Preinfarction angina (+) Preinfarction angina (-) 0 0 1 2 3 4 5 Years 0 0 1 2 3 4 5 Years Ishihara M et al., Am Heart J 2000

Myocardial ischemia evaluated by myocardial lactate extraction ratio (MLR) in adult and elderly patients during PTCA MLR (%) 60 p < 0.05 Baseline p < 0.05 Inflation 1 30 Inflation 2 0-30 -60-90 -120 p < 0.01 ADULT ELDERLY Lee T-M et al., Circulation 2002

(A) ISCHEMIC PRECONDITIONING PHASE (B) REPERFUSION INJURY SALVAGE KINASE adenosine opioids NE UCN bradykinin ANP-BNP 1 A δ α 1 UR NP A δ α 1 UR GR B 2 adenosine opioids NE UCN bradykinin IGF1-FGF-2 Reduction of NE release in response to preconditioning stimulus (Abete et al., 1996) B 2 GPCR RISK GPCR MPTP PI13K/Akt Reperfusion Injury PI13K enos NO Akt Salvage Kinase sgp GMP pgp GMP P70S6K PKG enos NO ROS p38 ERK 1/2 GSK3β (Mitochondrial Cx43 Permeability Failure of Transition translocation of Pore) PKC isoforms k ATP 4 Key role of MPTP Reduction of phosphorylating mitochondria connexin-43 (Boengler et al. 2007) 2 (Tani et al. 2001) PKC-ε PKC MPTP Enhanced dephosphorylation by protein phosphatases 3 (Fenton et al. 2005) MYOCARDIAL SURVIVAL

Cardioprotection and aging Cardioprotection: definition Myocardial stunning, hibernation, and ischemic preconditioning Cardioprotection and aging: why? Age-related reduction of cardioprotection Restoration of age-related reduction of cardioprotection Future directions

Drugs mimic ischemic preconditioning in different aging experimental model Nicorandil, mithocondrial ATP-K channel opener? Abete P et al., Ageing Res Rev 2009

Physical activity and mortality in older men with coronary heart disease Age-adjusted mortality (rate /1000 person years) 30 25 20 15 10 5 All cause Non-cardiovascular Cardiovascular 0 I nactive Occasional Light Moderate Moderately vigorous Vigorous Wannamethee SG et al., Lancet 1998

Body-mass index (BMI) and rate of death from cardiovascular disease Age-standardized rate (100.000 person/year) 8000 7000 6000 5000 4000 3000 2000 1000 0 23.5-24.9 28.0-29.9 >35 30-64 yr 65-74 yr 75 yr BMI Calle EE et al., N Engl J Med 1999

Lifestyle interventions in the elderly Usual aging Successful aging

Age-related reduction of ischemic preconditioning by exercise or food-restriction LVDP (% of baseline) 100 80 60 40 Exercised: 30 minutes swimming 5/days/week for 1months. Food-restriction: 60% of ad libitum fed from 12 to 24 months of age * * Ischemia - no IP Ischemia - IP 20 0 *p<0.05 vs no IP Controls Exercised Food-restricted Abete P et al., Ageing Res Rev 2009

Age-related reduction of ischemic preconditioning by exercise or food-restriction 30 Physical activity: PASE (Physical Activity Scale for the Eldelry) BMI: Body-mass index no ANGINA ANGINA In-hospital mortality (%) 20 10 0 *p<0.05 vs no ANGINA All patients * PASE >90 * BMI 19-24 Abete P et al., Ageing Res Rev 2009

Tandem action of exercise training and food restriction completely preserves ischemic preconditioning in the aging heart B IP Ischemia Riperfusion DP (%) 100 80 60 40 ADULTs SENESCENTs sedentary food-restricted trained trained and food-restricted 20 * * * 0-10 0 10 20 30 40 50 60 70 80 90 Time (mins) *p<0.05 vs SENESCENTs food-restricted and trained <0.01 vs ADULTs and SENESCENTs trained and food-restricted Abete P et al, Exp Gerontol, 2005

Mortality in elderly patient with AMI stratified for physical activity (PASE) and BMI 80 70 Mortality (%) 60 50 40 30 20 p < 0.002 p < 0.025 >27.0 p < 0.027 25.0-26.9 10 0 0-40 41-56 57-90 >90 p < 0.017 22.0-24.9 19.9-21.9 BMI PASE P. Abete et al., Eur J Card Rehab Prev 2009

Mortality in elderly patient with acute myocardial infarction stratified for physical activity (PASE) and BMI No Angina 80? 70 Mortality (%) 60 50 40 30 20 10 0 0-40 41-56 57-90 >90 p < 0.820 (NS) p < 0.452 (NS) >27.0 p < 0.3710 25.0-26.9 p < 0.392 (NS) 22.0-24.9 19.9-21.9 BMI PASE P. Abete et al., Eur J Card Rehab Prev 2009

Mortality in elderly patient with acute myocardial infarction stratified for physical activity (PASE) and BMI Angina 50% 80 70 Mortality (%) 60 50 40 30 3% p < 0.008 p < 0.028 >27.0 20 10 0 0-40 41-56 57-90 >90 25.0-26.9 p < 0.042 22.0-24.9 p < 0.023 19.9-21.9 BMI PASE P. Abete et al., Eur J Card Rehab Prev 2009

Role of preinfarction angina on mortality in elderly patient with acute myocardial infarction stratified for physical activity (PASE) and BMI Odds ratio % 7,0 3,0 2,5 2,0 1,5 1,0 0,5 0,0-0,5 sedentary overweight trained normal weight >27 26.9-25.0 24.9-22.0 21.9-19.0 PASE 0-40 41-56 57-90 > 90 BMI P. Abete et al., Eur J Card Rehab Prev 2009

Cardioprotection and aging Cardioprotection: definition Myocardial stunning, hibernation, and ischemic preconditioning Cardioprotection and aging: why? Age-related reduction of cardioprotection Restoration of age-related reduction of cardioprotection Future directions

Ischemic PRE-conditioning I R I R ISCHEMIA REPERFUSION PRE Ischemic POST-conditioning ISCHEMIA R I R I REPERFUSION POST

Aging mouse hearts are refractory to infarct size reduction with POST-CONDITIONING (post-pc) 100 Control Infarct size (% of LV) 80 60 40 20 * * Post-PC 0 Adult Senescent *p<0.05 vs control Przyklenk K et al., JACC 2008

AUTOPHAGY Induced by ischemic preconditioning (IPC) is essential for cardioprotection SHAM Non-IPC Transgenic mice expressing fluorescent fusion of protein mcherry-lc3 allow visualization of autophagosomes IPC Huang C et al., J Cardiovasc Trans Res, 2010

Inhibition of AUTOPHAGY reduces cardioprotection autophagy inhibitor=atg5 K130R Huang C et al., J Cardiovasc Trans Res, 2010

TAKE HOME MESSAGES Molecular mechanisms of adaptation to ischemia represent the endogenous cardioprotection. Myocardial sunning, hibernation and ischemic preconditioning represent the mechanism against myocardial ischemia in both animal and human studies. Experimental and clinical studies have demonstrated an age-related reduction of cardioprotection mechanisms. Exercise and caloric restriction are able to restore cardioprotection in the aging heart. Post-conditioning and autophagy should be taken into account in the next future.